← All trials
NCT04970342
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 16, 2021
- Primary completion
- Aug 21, 2021
- Completion date
- Aug 21, 2021
- First posted
- Jul 21, 2021
- Last posted
- Aug 26, 2021
- Enrollment
- 13
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of IowaLead sponsor
- University of IowaSponsor investigator
- Cognitive Research CorporationCollaborator
- Acclaro Research Solutions, Inc.Collaborator
- NHTSACollaborator
- University of IowaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.